Tesla
TSLA
Petroleo Brasileiro SA Petrobras
PBR
Apple
AAPL
KB Home
KBH
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
BCYC Bicycle Therapeutics
- 9.075
- +0.345+3.95%
Trading Mar 27 13:45 ET
628.01MMarket Cap-3.13P/E (TTM)
9.690High9.070Low407.13KVolume9.250Open8.730Pre Close3.77MTurnover0.92%Turnover RatioLossP/E (Static)69.20MShares28.67052wk High0.79P/B399.69MFloat Cap8.60052wk Low--Dividend TTM44.04MShs Float62.075Historical High--Div YieldTTM7.10%Amplitude6.240Historical Low9.261Avg Price1Lot Size
About Bicycle Therapeutics Company
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Company Profile
SymbolBCYC
Company NameBicycle Therapeutics
Listing DateMay 23, 2019
Issue Price14.00
Founded2009
CEODr. Kevin Lee, M.B.A.
MarketNASDAQ
Employees305
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressGranta Park Great Abington,Portway Building,Blocks A & B
CityCambridge
ProvinceCambridgeshire
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeCB21 6GS
Phone44-1223-261503
Company Executives
- Name
- Position
- Salary
- Dr. Kevin Lee, M.B.A.
- Director and Chief Executive Officer
- 5.54M
- Nigel Crockett
- Chief Business Officer
- --
- Alistair Milnes
- Chief Operating Officer
- --
- Dr. Santiago Arroyo
- Chief Development Officer
- 2.68M
- Dr. Nicholas Keen, PhD
- Chief Scientific Officer
- --
- Dr. Michael Skynner, PhD
- Chief Technology Officer
- --
- Dr. Michael Charles Ferguson Hannay, D.Sc.
- Chief Product and Supply Chain Officer
- --
- Alethia Young
- Chief Financial Officer
- 2.88M
- Travis Thompson
- Chief Accounting Officer
- --
- Pierre Legault, C.P.A.,M.B.A.
- Chairman of the Board
- 1.06M
- Sir Greg Winter, F.R.S.
- Independent Director
- 477.04K
- Janice Bourque, M.B.A.
- Independent Director
- 495.41K
- Stephen Sands
- Independent Director
- --
- Richard N. Kender, M.B.A.
- Independent Director
- 526.91K
- Dr. Jose-Carlos Gutierrez-Ramos, PhD
- Independent Director
- 482.29K
- Dr. Felix J. Baker,PhD
- Independent Director
- --
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.